CELLBION CO., LTDCC

CELLBION CO., LTD

13,250KRWD
−70−0.53%
At close at 09:42 UTC
KRW
No trades
See on Supercharts

308430 fundamentals

Key facts

Market capitalization‪170.51 B‬KRW
Founded2010
CEOKwon Kim
About

Cellbion Co., Ltd. engages in the research and development of imaging agents for diagnosis, cosmetics for hospitals, and functional health foods. It focus on the research and development of prostate cancer treatments. The company was founded by Kwon Kim on July 21, 2010 and is headquartered in Seoul, South Korea.

Ownership
‪‪12.80 M‬‬
Free Float shares
‪‪8.36 M‬‬ (65.31%)
Closely held shares
‪‪4.44 M‬‬ (34.69%)
Free Float shares
‪‪8.36 M‬‬ (65.31%)
Closely held shares
‪‪4.44 M‬‬ (34.69%)
Capital structure
Market cap
‪‪170.51 B‬‬
Debt
‪‪2.58 B‬‬
Cash & equivalents
‪‪6.76 B‬‬
Enterprise value
‪‪166.32 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪170.51 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
Q2 '24

Growth and Profitability

Company’s recent performance and margins

Performance
‪−514.0%‬
‪−510.5%‬
‪−507.0%‬
‪−503.5%‬
‪−500.0%‬
Q2 '24
‪‪−1.80 B‬‬
‪‪−1.20 B‬‬
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−1.80 B‬‬
‪‪−1.20 B‬‬
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−1.80 B‬‬
‪‪−1.20 B‬‬
‪‪−600.00 M‬‬
‪0.00‬
‪‪600.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Pharmaceutical
Other
By country
Period: 2023
South Korea

Dividends

Dividend yield, history and sustainability

308430 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q2 '24
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Assets
Liabilities